221024-29-9

Usage

General Description

1-Acetyl-5-bromo-7-chloroindoline is a chemical compound with the molecular formula C11H8BrClNO. It is a bright yellow solid with potential applications in organic synthesis and pharmaceuticals. 1-ACETYL-5-BROMO-7-CHLOROINDOLINE contains an indoline ring system with acetyl, bromo, and chloro substituents. It is commonly used in the preparation of specialized dyes and pigments due to its vibrant color properties. Additionally, it may have potential biological activity and medicinal uses, although further research is needed to fully understand its potential applications.

Upstream product

• 22190-38-1 5-bromo-N-acetylindoline 
• 22190-33-6 5-bromoindoline 

Downstream Products

• 424834-57-1 5-formyl-7-chloroindole 
• 180623-89-6 5-bromo-7-chloro-1H-indole 
• 221024-31-3 5-bromo-7-chloro-indoline 

Relevant academic research and scientific papers

COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF

The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.

Potent, orally active heterocycle-based combretastatin A-4 analogues: Synthesis, structure - Activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation

The synthesis and structure - activity relationship study of a series of compounds with heterocycles in place of the cis double bond in combretastatin A-4 (CA-4) are described. Substituted tosylmethyl isocyanides were found to be the key intermediates in construction of the heterocycles. Cytotoxicities of the heterocycle-based CA-4 analogues were evaluated against NCI-H460 and HCT-15 cancer cell lines. 3-Amino-4-methoxyphenyl and N-methyl-indol-5-yl were the best replacements for the 3-hydroxy-4-methoxyphenyl in CA-4. 4,5-Disubstituted imidazole was found to be the best for the replacement of the cis double bond in CA-4. Medicinal chemistry efforts led to the discovery of compounds 24h and 25f that were found to be 32 and 82% bioavailable, respectively, in rat. Evaluation of 24h and 25f against murine M5076 reticulum sarcoma in mice revealed that both compounds were orally efficacious with an increase in life span of 38.5 and 40.5%, respectively.

Oxazoline antiproliferative agents

Compounds having Formula I are useful for treating cancer. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of treating cancer in a mammal.

Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders

Corticotropin releasing factor (CRF) antagonists of Formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.